Ten-Year Changes in Breast Cancer Care Across Turkish Centers
Researchers compared breast cancer care practices and center infrastructure in Turkiye between 2009 and 2019 and found several procedural shifts. The evidence is based on a repeated institutional survey comparing data from two specific years, but individual patient survival outcomes were not available.
In short: Researchers compared breast cancer care practices and center infrastructure in Turkiye between 2009 and 2019 and found several procedural shifts. The evidence is based on a repeated institutional survey comparing data from two specific years, but individual patient survival outcomes were not available.
How did hospitals change the way they handle breast cancer care over a span of ten years?
What happened, in plain words
A team of researchers evaluated how breast cancer management, diagnostic tools, and treatments changed in specialized breast centers in Turkiye by comparing data from 2009 and 2019. Thirty-eight centers provided information in 2009, and 44 centers contributed in 2019, with the number of confirmed cases rising from 4,808 to 6,550. The study tracked updates in diagnostic methods, surgeries, imaging availability, and specialized support services.
Key points
- Growth in participating centers and cases: Thirty-eight centers took part in 2009, while 44 centers participated in 2019. The total number of confirmed breast cancer cases reported grew from 4,808 to 6,550.
- Changes in diagnostic methods: Core needle biopsies mostly replaced older excisional or incisional procedures for diagnosis. The availability of diagnostic imaging also improved across the participating institutions.
- Shifts in surgical practices: Surgical care moved more toward breast-conserving surgery. Additionally, the reported use of sentinel lymph node biopsies increased from about 48% to 55%.
- Expanded support and treatments: The use of neoadjuvant therapy grew. Medical oncology and chemotherapy units, as well as lymphedema services, also saw improvements in their availability.
Terms explained
- Tertiary breast centers — Specialized hospital facilities that handle advanced medical care and complex treatments. Example: A large regional hospital where patients are sent for specialized cancer operations.
- Neoadjuvant therapy — Medical treatments given as a first step before the main treatment, such as surgery, to shrink tumors. Example: Receiving medicine to shrink a growth prior to having an operation.
- Sentinel lymph node biopsy — A surgical procedure used to check if cancer has spread to the nearest lymph nodes. Example: Sampling the very first lymph node where draining fluid from a tumor would flow.
Critical analysis
What is encouraging. The study offers a broad look at institutional changes across multiple centers over a decade, highlighting clear shifts in diagnostic preferences and treatment availability in Turkiye.
What deserves caution:
- Aggregated center-level data. The study relied on grouped data from centers rather than individual patient records. This setup prevents researchers from evaluating specific patient-level choices or individual health outcomes.
- Missing survival outcomes. Individual recurrence rates and overall survival outcomes were completely unavailable in the dataset. Therefore, the report cannot state whether these procedural shifts improved patient survival.
- Unclear appropriateness of procedures. The dataset lacked clinical nodal status and patient-level indications for specific surgeries like sentinel lymph node biopsies. Because of this, the actual clinical appropriateness of those axillary procedures cannot be assessed.
- Uneven progress across domains. While certain areas improved, progress remained uneven across multidisciplinary and supportive-care domains. The source does not provide a uniform picture of growth in every single category of care.
Bottom line: While institutional practices and infrastructure in Turkish breast centers changed noticeably between 2009 and 2019, the lack of patient-level outcome data means the impact on survival remains unknown.
What we still don't know
The source does not provide individual recurrence outcomes, overall survival data, patient-level treatment indications, or clinical nodal status. Progress across supportive-care and multidisciplinary domains was uneven, and the appropriateness of individual axillary procedures could not be determined.
Based on reporting from Scientific Reports. This is an independent explainer, written in our own words with AI assistance; Scientific Reports has not reviewed or endorsed it. Read the original for the full details.